Celeco100 mg

Celeco is a selective cyclooxygenase-2 (COX-2) inhibitor NSAID with the following evidence-based indications:

Established / FDA-approved uses

• Osteoarthritis (OA): relief of signs and symptoms.
• Rheumatoid arthritis (RA): relief of signs and symptoms in adults.
• Ankylosing spondylitis: relief of signs and symptoms.
• Acute pain in adults (e.g. post-surgical or musculoskeletal pain).
• Primary dysmenorrhea: management of menstrual pain.
• Juvenile rheumatoid arthritis (JRA) in children 2 years of age and older (relief of signs and symptoms).

Guideline-supported / adjunct uses

• Adjunctive reduction of adenomatous colorectal polyps in familial adenomatous polyposis (FAP), as an addition to usual care (surgery, endoscopic surveillance), not as a replacement for these.

Celeco is not indicated for minor aches or short-term self-limited pain when safer alternatives are appropriate, and should always be used at the lowest effective dose for the shortest duration needed.

Each capsule contains Celecoxib as the active pharmaceutical ingredient, commonly available in strengths of 100 mg and 200 mg. Inactive excipients (fillers, lubricants, capsule shell components) vary by manufacturer/brand.

Celeco is a diaryl-substituted pyrazole compound belonging to the class of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively inhibit the cyclooxygenase-2 (COX-2) isoenzyme. Unlike traditional non-selective NSAIDs, Celeco at therapeutic doses has minimal effect on the COX-1 isoenzyme, which is thought to reduce (but not eliminate) the risk of gastrointestinal ulceration and bleeding compared with non-selective NSAIDs, while still exerting anti-inflammatory, analgesic, and antipyretic effects.

Celeco is supplied as oral capsules and is used across a range of musculoskeletal and pain conditions, as detailed under Indications.

Selective COX-2 inhibitor; Nonsteroidal Anti-Inflammatory Drug (NSAID) subclass — Celeco belongs to the coxib class.

Celecoxib works by selectively inhibiting cyclooxygenase-2 (COX-2), the inducible enzyme responsible for producing prostaglandins involved in pain, inflammation, and fever at sites of tissue injury. By sparing cyclooxygenase-1 (COX-1) — the constitutive enzyme responsible for maintaining protective gastric mucosa and normal platelet function — at recommended doses, Celecoxib produces anti-inflammatory, analgesic, and antipyretic effects with a comparatively lower incidence of endoscopic GI ulceration than non-selective NSAIDs, although clinically significant GI events can still occur.

Pharmacokinetics: Celecoxib is well absorbed orally, reaching peak plasma concentration in about 2–3 hours; it is highly protein-bound (>97%), extensively metabolized in the liver primarily via the CYP2C9 enzyme pathway, and has an elimination half-life of approximately 11 hours, supporting once- or twice-daily dosing depending on indication. Individuals who are poor CYP2C9 metabolizers can have substantially higher plasma levels.

Celeco is administered orally, with or without food. Capsules can be swallowed whole or the contents sprinkled on applesauce for patients with difficulty swallowing. Consistent timing each day helps maintain steady drug levels.

Celeco has the following well-established, clinically significant drug interactions:

• Warfarin and other anticoagulants: increased risk of bleeding; monitor prothrombin time/INR closely, especially when starting or changing the dose of Celeco.
• Fluconazole: a strong CYP2C9 inhibitor that approximately doubles Celeco plasma concentrations; consider starting Celeco at the lowest recommended dose.
• Lithium: Celeco can increase plasma lithium levels; monitor for lithium toxicity.
• ACE inhibitors, angiotensin receptor blockers (ARBs), and diuretics: Celeco may reduce their antihypertensive effect and increase risk of acute kidney injury, particularly in volume-depleted patients.
• Aspirin and other NSAIDs: concurrent use increases the risk of GI ulceration and bleeding without added clinical benefit, and is generally avoided.
• Corticosteroids and SSRIs/SNRIs: concurrent use with Celeco increases the risk of GI bleeding.
• Methotrexate: Celeco may increase methotrexate plasma levels; monitor for methotrexate toxicity.

Common side effects (occurring in more than 2% of patients) associated with Celeco include:

• Abdominal pain, dyspepsia, diarrhea, flatulence, nausea
• Headache, dizziness
• Peripheral edema
• Upper respiratory tract infection symptoms
• Rash
• Insomnia

Serious but less common effects requiring immediate medical attention include signs of GI bleeding (black/bloody stools, vomiting blood), signs of cardiovascular events (chest pain, shortness of breath, weakness on one side of the body, slurred speech), severe skin reactions (blistering, peeling rash), signs of liver injury (jaundice, dark urine), and hypersensitivity reactions (facial swelling, difficulty breathing).

Pregnancy: Use of Celeco should generally be avoided in pregnancy, particularly starting at 20 weeks gestation, when NSAID use has been associated with fetal renal dysfunction that can lead to oligohydramnios, and in some cases neonatal renal impairment. Celeco is contraindicated in the third trimester due to the risk of premature closure of the fetal ductus arteriosus. If use is considered necessary between 20 and 30 weeks, it should be limited to the lowest effective dose for the shortest possible duration, only if clearly needed and the potential benefit justifies the potential risk to the fetus; consult a physician before use at any stage of pregnancy.

Lactation: Celeco is excreted in low levels into human breast milk. Because of the potential for serious adverse effects in a nursing infant, a decision should be made whether to discontinue nursing or discontinue Celeco, taking into account the importance of the drug to the mother; consult a physician before use while breastfeeding.

Boxed Warnings

• Cardiovascular thrombotic risk: NSAIDs including Celeco can increase the risk of serious, potentially fatal cardiovascular thrombotic events including myocardial infarction and stroke. This risk may increase with duration of use and is elevated in patients with, or at high risk for, cardiovascular disease.
• Gastrointestinal risk: NSAIDs including Celeco increase the risk of serious GI adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal; these events can occur at any time and without warning symptoms.
• Contraindicated in CABG surgery perioperative setting (see Contraindications).

Other precautions

• Use with caution in patients with a prior history of peptic ulcer disease or GI bleeding.
• Use with caution in renal impairment, heart failure, hypertension, or in dehydrated patients, as NSAIDs can worsen renal function and fluid retention.
• Use with caution in patients on concurrent anticoagulants, corticosteroids, other NSAIDs, or SSRIs due to increased bleeding risk (see Interactions).
• Elderly patients are at greater risk for GI and cardiovascular adverse events.
• Serious skin reactions (including Stevens-Johnson syndrome and toxic epidermal necrolysis) have been reported rarely; discontinue at the first sign of skin rash or hypersensitivity.
• Celeco contains a sulfonamide moiety; use caution in patients with sulfa allergy (see Contraindications).
• Use the lowest effective dose of Celeco for the shortest duration consistent with individual treatment goals.

Symptoms of Celeco overdose may include lethargy, drowsiness, nausea, vomiting, and epigastric pain; more severe toxicity such as gastrointestinal bleeding, hypertension, acute kidney injury, respiratory depression, or coma is possible with very large ingestions. There is no specific antidote. In case of suspected overdose, seek immediate medical attention or contact a poison control center / emergency services right away. Management is supportive and symptomatic; because Celeco is highly protein-bound, dialysis is unlikely to be effective in enhancing elimination.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric use

Celeco is approved for relief of signs and symptoms of juvenile rheumatoid arthritis (JRA) in children 2 years of age and older, at weight-based doses (see Dosage and Administration). Safety and effectiveness in children below 2 years of age, or for indications other than JRA, have not been established.

Elderly

Elderly patients are at increased risk of GI bleeding, cardiovascular events, and renal impairment with Celeco; use the lowest effective dose and monitor closely.

Renal impairment

Use with caution in mild-to-moderate renal impairment; not recommended in patients with severe renal impairment (see Dosage and Administration).

Hepatic impairment

Dose reduction of approximately 50% is recommended in moderate hepatic impairment; use in severe hepatic impairment is not recommended (see Dosage and Administration).

Duration of treatment with Celeco depends on the condition being treated. For acute pain and primary dysmenorrhea, short courses of a few days are typical. For chronic conditions such as osteoarthritis, rheumatoid arthritis, or ankylosing spondylitis, treatment may continue longer term under medical supervision, but the lowest effective dose should always be used for the shortest duration consistent with individual treatment goals, given cardiovascular and GI risks that can increase with prolonged use.

Nonsteroidal Anti-Inflammatory Drug (NSAID) — Selective COX-2 Inhibitor (Coxib class).

Celecoxib selectively inhibits the cyclooxygenase-2 (COX-2) enzyme, which is induced at sites of inflammation and is responsible for synthesizing prostaglandins that mediate pain, inflammation, and fever. By preferentially sparing cyclooxygenase-1 (COX-1) at therapeutic doses — the enzyme responsible for protective gastric prostaglandins and normal platelet thromboxane production — Celecoxib achieves anti-inflammatory and analgesic effects with less impact on gastric mucosal protection and platelet aggregation compared to non-selective NSAIDs, though it does not eliminate GI or cardiovascular risk.

Category C (before 30 weeks gestation); Category D (at 30 weeks gestation and later) — legacy FDA pregnancy category.

Celeco is approved for the relief of signs and symptoms of juvenile rheumatoid arthritis (JRA) in patients 2 years of age and older, dosed by body weight: 50 mg twice daily for children weighing 10–25 kg, and 100 mg twice daily for children weighing more than 25 kg. Safety and efficacy of Celeco have not been established in children under 2 years of age or for indications other than JRA. As with adults, the lowest effective dose for the shortest duration should be used, and children should be monitored for GI and other adverse effects.